[Oral steroid contraception in hyperprolactinemia (author's transl)]

Area of Science:

• Endocrinology
• Reproductive Health
• Pharmacology

Context:

• Hyperprolactinemia is a condition characterized by elevated prolactin levels.
• Oral contraceptives are widely used for birth control and hormone replacement therapy.
• The potential link between steroid medications and hyperprolactinemia requires investigation.

Purpose:

• To investigate the statistical correlation between oral contraceptives and hyperprolactinemia.
• To assess the risk of developing or maintaining hyperprolactinemia with oral contraceptive use.
• To evaluate the impact of oral contraceptives on existing pituitary adenomas.

Summary:

• A case-control study compared 91 women with hyperprolactinemia-amenorrhea to 91 women with amenorrhea and normal prolactin levels.
• Results indicated that oral contraceptives (estrogen and progesterone combinations) do not increase the relative risk for functional or adenomatous hyperprolactinemia.
• No evidence suggested deterioration of existing pituitary adenomas during oral contraception, though two cases of pituitary adenoma followed long-term high-dose estrogen therapy.

Impact:

• Low-dose steroid medications do not appear to increase the risk for the development or maintenance of hyperprolactinemia.
• Findings suggest oral contraceptives are safe concerning hyperprolactinemia in matched patient groups.
• Further research may be warranted for high-dose or long-term estrogen therapy effects.